Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab

BACKGROUND: The role of continuing anti-HER2 therapy beyond progression on front-line therapy in patients with metastatic HER2 positive gastro-oesophageal cancer (GEC) is unclear. Continued chemotherapy plus trastuzumab (CT) has never been compared with the current standard second-line treatment, ch...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:ESMO Open
Main Authors: Nevala-Plagemann, Christopher, Moser, Justin, Gilcrease, Glynn Weldon, Garrido-Laguna, Ignacio
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2019
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6677976/
https://ncbi.nlm.nih.gov/pubmed/31423338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000539
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares